Charlotte Schubert

4 weeks ago | medicalxpress.com | Charlotte Schubert |Sadie Harley |Andrew Zinin

A new four-drug combination is highly effective and safe in patients with newly diagnosed multiple myeloma, according to data presented at the annual meeting of the American Society of Clinical Oncology (ASCO), held May 30 through June 3 in Chicago. The data emerged from the ADVANCE clinical trial led by Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

1 month ago | news.med.miami.edu | Charlotte Schubert

By: Charlotte Schubert, Ph.D. | May 09, 2025 | 7 min. read |  Share SummaryIDH-wildtype glioblastoma inevitably returns after treatment and has an extremely poor prognosis. Two new tumor profiling studies offer insights into how to classify such brain tumors and how they evolve after treatment.

2 months ago | news.med.miami.edu | Charlotte Schubert

Home  /  News  /  Research and Innovation  /  Biochemistry and Molecular Biology By: Charlotte Schubert, Ph.D. | April 11, 2025 | 9 min.

2 months ago | news.med.miami.edu | Charlotte Schubert

By: Charlotte Schubert, Ph.D. | April 10, 2025 | 7 min. read |  Share SummaryCancer research is shifting after a key ruling at the FDA that was based on data from Sylvester researchers. An FDA panel green-lit a new way to measure success in multiple myeloma clinical trials, using a measurement called minimal residual disease.

2 months ago | news.med.miami.edu | Charlotte Schubert

By: Charlotte Schubert, Ph.D. | April 08, 2025 | 11 min. read |  Share SummaryA new two-year, team science award at Sylvester is exploring how metabolism, body composition and circadian rhythms intersect in renal cell carcinoma, the most common form of kidney cancer.